Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
- DOI
- 10.1016/j.ygyno.2023.01.020
- Published
- 2023-03
- Container
- Gynecologic Oncology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.ygyno.2023.01.020,
title = {Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer},
author = {Lucy Gilbert and Ana Oaknin and Ursula A. Matulonis and Gina M. Mantia-Smaldone and Peter C. Lim and Cesar M. Castro and Diane Provencher and Sanaz Memarzadeh and Michael Method and Jiuzhou Wang and Kathleen N. Moore and David M. O'Malley},
year = {2023},
journal = {Gynecologic Oncology},
doi = {10.1016/j.ygyno.2023.01.020},
url = {https://doi.org/10.1016/j.ygyno.2023.01.020}
}RIS
TY - JOUR TI - Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer AU - Lucy Gilbert AU - Ana Oaknin AU - Ursula A. Matulonis AU - Gina M. Mantia-Smaldone AU - Peter C. Lim AU - Cesar M. Castro AU - Diane Provencher AU - Sanaz Memarzadeh AU - Michael Method AU - Jiuzhou Wang AU - Kathleen N. Moore AU - David M. O'Malley PY - 2023 JO - Gynecologic Oncology DO - 10.1016/j.ygyno.2023.01.020 UR - https://doi.org/10.1016/j.ygyno.2023.01.020 ER -
APA
Gilbert, L., Oaknin, A., Matulonis, U. A., Mantia-Smaldone, G. M., Lim, P. C., Castro, C. M., Provencher, D., Memarzadeh, S., Method, M., Wang, J., Moore, K. N., & O'Malley, D. M. (2023). Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2023.01.020
Source records
- crossref · retrieved 2026-11-11T00:10:01.288Z